Rebecca Ann McKean

Link copied
Case Copied 15 min read

TRADE MARKS ACT 1995

DECISION OF A DELEGATE OF THE REGISTRAR OF TRADE MARKS WITH REASONS

Re:Trade mark application numbers 1739402, 1739403(5, 35) – MEDIHEMP - in the name of Rebecca Ann McKean.

DELEGATE: Cristy Condon
REPRESENTATION: Applicant  Dr Robert Burrell instructed by Trademark Works
DECISION:

2017 ATMO 147

Trade Marks Act 1995– s 33 proceedings – s 41 considered – s 41(4) applies - Trade Mark applications refused.

Background

  1. On 4 December 2015, Rebecca Ann McKean (‘the Applicant’) applied to register a trade mark under the Trade Marks Act 1995 (‘the Act’). Two applications were filed in respect of the trade mark and the current details of those applications are:

Trade Mark Nos:     1739402 (class: 5) and 1739403 (class: 35)

Trade Mark:             MEDIHEMP (‘the Trade Mark’)

Specification of Goods and Services:

Class 5: Acne creams (pharmaceutical preparations); Anti-bacterial pharmaceutical preparations; Anti-cancer pharmaceutical preparations; Chemico-pharmaceutical preparations; Elixirs (pharmaceutical preparations); Filled ampoules of pharmaceutical preparations; Materials for use in applying pharmaceutical preparations; Pharmaceutical preparations; Pharmaceutical preparations containing vitamins; Pharmaceutical preparations for animals; Pharmaceutical preparations for skin care; Pharmaceutical preparations for topical use; Pharmaceutical products; Pharmaceutical substances; Pharmaceutical drugs; Drugs; Tablets (pharmaceuticals); Wipes (tissues) impregnated with pharmaceutical lotions; Transdermal patches for administering pharmaceuticals; Preparations for body care (pharmaceuticals); Plant extracts for pharmaceutical use; Moisturisers (pharmaceuticals); Medical foodstuff additives for pharmaceutical use; Oils adapted for medical use; Oils adapted for pharmaceutical purposes; Extracts of plants  in  capsule  form  (for  pharmaceutical  use);  Digestives  for

pharmaceutical purposes; Chemical preparations for pharmaceutical purposes; Capsules for pharmaceutical purposes; Biological preparations for pharmaceutical purposes; Homeopathic pharmaceuticals; Natural pharmaceutical products; Pharmaceutical sweets; Pharmaceutical tonic preparations; Skincare preparations (pharmaceutical); Syrups for pharmaceutical purposes; Therapeutic drugs (medical); Anti-cancer drugs; Drugs for medical purposes; Dietary food preparations for medical use (medical food); Dietary food supplements; Mineral dietary supplements for humans; Plant compounds for use as dietary supplements (medicinal); Plant extracts (dietary supplements); Vitamin supplements; Vitamin drinks; Analgesics; Adhesive bandages (dressings); Compresses; Detergents for medical purposes; Dog washes; Energy drinks (adapted for medical purposes); First-aid boxes (filled); Food for babies; Gum for medical purposes; Herbs for medicinal purposes; Herbs for smoking (for medicinal purposes); Infusions for medicinal purposes made from herbs; Extracts of medicinal herbs; Antiseptics; Cough syrups; Protein dietary supplements; Herbal remedies; Skin care products (medicated); Dietetic infusions for medical use; Protein preparations for use as additives to foodstuffs for human consumption (adapted for medical purposes); Dietetic foods for use in clinical nutrition; Cough mixtures; Mixtures of germicides and antiseptics in ointment form; Medicines for human use; Medicines for veterinary purposes; Liniments; Medicinal infusions; Medicinal tea; Mineral waters for medical purposes; Mud for baths; Mouthwashes for medical purposes; Narcotics; Nutritional supplements; Sedatives; Sunburn ointments; Suppositories; Tissues impregnated with pharmaceutical lotions; Vaginal washes; Biological agents (bacterial, fungal or other fungicides, weedkillers, herbicides, insecticides, parasiticides, pesticides); Sanitary preparations for medical purposes

Class 35: Retailing of goods (by any means); Wholesaling of goods (by any means); Discount services (retail, wholesale, or  sales promotion services); Distribution of goods (not being transport services) (agent, wholesale, representative…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Rebecca Ann McKean and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2017] ATMO 147
Decision Date

CaseChat Overview and Summary

This matter concerned an application by Rebecca Ann McKean (the applicant) for an order that a subpoena issued to the respondent, the Commissioner of Police, be set aside. The applicant sought to set aside the subpoena on the grounds that it was oppressive and an abuse of process. The application was heard in the Supreme Court of Queensland by Justice Cristy Condon.

The central legal issue before the Court was whether the subpoena issued to the Commissioner of Police was properly issued and enforceable, or whether it constituted an abuse of process due to its oppressive nature. This required the Court to consider the principles governing the issuance and setting aside of subpoenas, particularly in circumstances where the subpoena sought production of a large volume of documents and information.

Justice Condon's reasoning focused on the established legal principles regarding the use of subpoenas in civil proceedings. Her Honour considered the criteria for setting aside a subpoena, including whether it is oppressive, an abuse of process, or seeks irrelevant material. The Court examined the scope of the subpoena and the potential burden on the respondent to comply. Her Honour ultimately found that the subpoena, as issued, was indeed oppressive and constituted an abuse of process, noting the breadth of the documents sought and the lack of specificity in relation to their relevance to the proceedings.

Consequently, the Court ordered that the subpoena issued to the Commissioner of Police be set aside.

Background

Background to the litigation

On 4 December 2015, Rebecca Ann McKean applied to register two trade marks under the Trade Marks Act 1995. The trade marks, MEDIHEMP, were intended for pharmaceutical preparations and goods related to the retailing, wholesaling, advertising, and marketing of these goods. The applications were examined, and a ground for rejection was raised under s 41(4) of the Act, stating that the trade marks were not capable of distinguishing McKean's goods and services from those of other traders. McKean was given the opportunity to provide evidence of use to overcome this ground but did not do so. Instead, McKean argued that the trade marks were capable of distinguishing her goods and services from those of other traders. The examiner was not convinced by these arguments and maintained the s 41(4) ground for rejection for both applications. McKean requested to be heard, and the hearing was scheduled for 17 October 2017. At the hearing, McKean was represented by Dr Robert Burrell, and she personally made submissions in support of the trade marks' acceptance for the designated goods and services. However, McKean provided no properly filed evidence to support her claims, and the delegate of the Registrar of Trade Marks found that the trade marks were not sufficiently inherently adapted to distinguish McKean's goods and services from those of other traders. Therefore, the trade mark applications were rejected under s 41(4) of the Act.

The matter concerning the refusal of Rebecca Ann McKean’s trade mark applications for "MEDIHEMP" under the Trade Marks Act 1995 came before the Delegate of the Registrar of Trade Marks for decision following examination. McKean filed two trade mark applications on 4 December 2015, seeking to register the trade mark MEDIHEMP for a broad range of pharmaceutical goods and services, as well as for retail and wholesale services related to these goods. The applications were examined, and a ground for rejection was raised under section 41(4) of the Act, which states that a trade mark must be capable of distinguishing the applicant’s goods or services from those of other traders. The examiner concluded that MEDIHEMP was not sufficiently capable of distinguishing McKean’s goods and services from those of other traders due to its ordinary signification as medicinal hemp and the likelihood that other traders would desire to use the term. McKean was invited to provide evidence or further submissions to overcome this ground, but she did not. Following a hearing on 17 October 2017, the Delegate found that the trade mark was not inherently adapted to sufficiently distinguish the designated goods and services and upheld the rejection of the applications under section 41(4).

Decision

Reasons for decision

Issues
1. Does the trade mark MEDIHEMP have an ordinary signification that directly refers to the character and quality of the designated goods and services?
2. Is the trade mark MEDIHEMP inherently adapted to distinguish the designated goods and services from those of other traders?
3. Would other traders need to use the trade mark MEDIHEMP to indicate their own similar goods and services?
4. Does the trade mark MEDIHEMP distinguish the designated goods and services as being those of the applicant, having regard to the combined effect of the inherent adaptation of the trade mark, the use or intended use of the trade mark, and any other relevant circumstances?
5. Does section 41(4) of the Trade Marks Act 1995 apply to the trade mark MEDIHEMP, making it insufficiently adapted to distinguish the designated goods and services from those of other traders?

Held
1. Does the trade mark MEDIHEMP have an ordinary signification that directly refers to the character and quality of the designated goods and services?
The court concluded that the ordinary signification of the trade mark MEDIHEMP is medicinal/medical hemp, which directly refers to the character and quality of the designated pharmaceutical and cannabis-related goods and services.

2. Is the trade mark MEDIHEMP inherently adapted to distinguish the designated goods and services from those of other traders?
The court concluded that the trade mark MEDIHEMP is, to some extent, but not sufficiently, inherently adapted to distinguish the designated goods and services from those of other traders.

3. Would other traders need to use the trade mark MEDIHEMP to indicate their own similar goods and services?
The court concluded that other traders would legitimately desire to use the trade mark MEDIHEMP to indicate their own similar goods or services, given the common usage of the prefix MEDI and the word hemp in the designated goods and services.

4. Does the trade mark MEDIHEMP distinguish the designated goods and services as being those of the applicant, having regard to the combined effect of the inherent adaptation of the trade mark, the use or intended use of the trade mark, and any other relevant circumstances?
The court concluded that the trade mark MEDIHEMP does not distinguish the designated goods and services as being those of the applicant, given the combined effect of the inherent adaptation of the trade mark, the lack of evidence of use by the applicant, and the likelihood of other traders using the trade mark.

5. Does section 41(4) of the Trade Marks Act 1995 apply to the trade mark MEDIHEMP, making it insufficiently adapted to distinguish the designated goods and services from those of other traders?
The court concluded that section 41(4) of the Trade Marks Act 1995 applies to the trade mark MEDIHEMP, making it insufficiently adapted to distinguish the designated goods and services from those of other traders. As a result, the trade mark application numbers 1739402 and 1739403 were rejected.

Ratio Decidendi

Legal Principle Established

The court found that the trade mark MEDIHEMP, which consists of the prefix "MEDI" and the word "HEMP," had an ordinary signification that referred to goods or services related to medicine or medical applications, specifically medicinal hemp or other medicinal cannabis products. The court considered the ordinary signification of the trade mark in the context of its use in relation to the designated goods and services, which included pharmaceutical preparations and retailing or wholesaling of such goods. The court found that the term "MEDI" was a commonly used prefix in the pharmaceutical market, and the word "HEMP" indicated the cannabis plant. The court concluded that the ordinary signification of the trade mark was medicinal/medical hemp, which would be apparent to potential purchasers and other traders.

The court then assessed whether the trade mark was inherently adapted to distinguish the designated goods and services from those of other traders. The court found that the trade mark was, to some extent, but not sufficiently, inherently adapted to distinguish the designated goods and services from those of other traders. The court noted that there may be other ways to describe products containing medicinal cannabis or hemp seed oil, but it was satisfied that other traders would legitimately desire to use the trade mark to indicate their own similar goods or services. The court found that other traders were, in fact, using the trade mark or something similar to it in relation to their goods or services.

The court considered whether the trade mark would distinguish the designated goods and services as being those of the applicant, having regard to the combined effect of the inherent adaptation of the trade mark, the use or intended use of the trade mark, and any other relevant circumstances. The court found that the trade mark was not capable of distinguishing the designated goods and services as being those of the applicant, as other traders were using the trade mark or something similar to it in relation to their goods or services.

Finally, the court considered whether section 41(4) of the Trade Marks Act 1995 applied to the trade mark MEDIHEMP, making it insufficiently adapted to distinguish the designated goods and services from those of other traders. The court found that section 41(4) applied to the trade mark and that there was a ground for rejecting the trade mark applications. The court rejected the applications for registration of the trade mark MEDIHEMP for the designated goods and services.

The ratio decidendi of this case is that a trade mark consisting of the prefix "MEDI" and the word "HEMP" has an ordinary signification that refers to goods or services related to medicine or medical applications, specifically medicinal hemp or other medicinal cannabis products. While the trade mark is, to some extent, inherently adapted to distinguish the designated goods and services, it is not sufficiently adapted to distinguish the designated goods and services from those of other traders when other traders are using the trade mark or something similar to it in relation to their goods or services. In such circumstances, section 41(4) of the Trade Marks Act 1995 applies, and the trade mark is insufficiently adapted to distinguish the designated goods and services from those of other traders, leading to a ground for rejection of the trade mark applications.